Turkish Journal of Biology
Volume 45
Number 7 SI-4

Article 10

1-1-2021

The current state of validated small molecules inhibiting SARSCoV-2 non-structural proteins
FATİH KOCABAŞ
MERVE USLU

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
KOCABAŞ, FATİH and USLU, MERVE (2021) "The current state of validated small molecules inhibiting
SARS-CoV-2 non-structural proteins," Turkish Journal of Biology: Vol. 45: No. 7, Article 10. https://doi.org/
10.3906/biy-2106-42
Available at: https://journals.tubitak.gov.tr/biology/vol45/iss7/10

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology
http://journals.tubitak.gov.tr/biology/

Review Article

Turk J Biol
(2021) 45: 469-483
© TÜBİTAK
doi:10.3906/biy-2106-42

The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural
proteins
Fatih KOCABAŞ*, Merve USLU
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkey
Received: 20.08.2021

Accepted/Published Online: 06.08.2021

Final Version: 30.08.2021

Abstract: The current COVID-19 outbreak has had a profound influence on public health and daily life. Despite all restrictions and
vaccination programs, COVID-19 still can lead to fatality due to a lack of COVID-19-specific treatments. A number of studies have
demonstrated the feasibility to develop therapeutics by targeting underlying components of the viral proteome. Here we reviewed
recently developed and validated small molecule inhibitors of SARS-CoV-2’s nonstructural proteins. We described the validation
level of identified compounds specific for SARS-CoV-2 in the presence of in vitro and in vivo supporting data. The mechanisms of
pharmacological activity, as well as approaches for developing improved SARS-CoV-2 NSP inhibitors have been emphasized.
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1. Introduction
Coronaviruses (CoVs) are enveloped positive-stranded
RNA viruses that typically result in respiratory infections
(Alam et al., 2020). Coronaviruses infections were
considered relatively benign to humans before the severe
acute respiratory syndrome (SARS) (Taştan et al., 2020).
As of August 2021, an estimated 198 million people have
been infected worldwide by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and caused over
4.2 million deaths (World Health Organization, 2021).
There are no specific therapies against COVID-19, which
urges the identification of potential therapeutic targets and
the development of COVID-19 therapies.
SARS-CoV-2 is a member of the β-coronavirus family
that possesses the large Spike proteins on the surface of the
virus that forms their crown-like shape. The viral genome
consists of up to 32,000 bases (Jena et al., 2021). The genomic
RNA consists of a variable number of open reading frames
(ORFs) (Jena et al., 2021). It has been stated that the viral
genome encodes approximately 29 proteins composed of 4
structural proteins and 25 nonstructural proteins (NSPs)
and accessory proteins (Hasöksüz et al., 2020; Güler et al.,
2021; Jena et al., 2021). ORF 1ab of SARS-CoV-2 encodes
NSPs and takes part in the translation of two polypeptides
known as pp1a and pp1ab. The nonstructural protein
pp1a comprises NSP1 to NSP11 and pp1ab corresponds

to NSP12 to NSP16 (Hasöksüz et al., 2020). The 10,000kb
region through 3’end encodes structural proteins
named membrane (M), envelope (E), surface (S), and
nucleocapsid (N). The SARS-CoV-2 viruses are enveloped,
spherical and their size is about 80–120 nm in diameter
(Petrosillo et al., 2020; Güler et al., 2021). Due to the many
outward homotrimeric glycosylated S protein projections,
their appearance resembles a solar corona (Bulut and Kato
2020). The capsid contains the N protein and is further
encircled with a membrane including the M protein and
the E protein that are participating in virus budding, and
the spike glycoprotein, which is important for binding the
host receptor following membrane fusion and the entry
of virus in the host cells. Along with these four structural
proteins, nine accessory proteins ORF3a, ORF3b, ORF6,
ORF7a, ORF7b, ORF8, ORF9b, ORF9c, and ORF10 are
encoded at the 3’ end as well (Güler et al., 2021). Accessory
proteins were considered to participate in the virulence as
well as the host-virus interactions.
SARS-CoV-2’s spike protein binds to its cognate host
cell receptor, which is angiotensin-converting enzyme 2
(ACE2) (Hasöksüz et al., 2020). After the fusion inside
the host cells, the viral genome is delivered as a singlestranded RNA, which is replicated by RNA-dependent
RNA polymerase (RdRp) protein to generate viral
genomes. Thereafter, the translation of viral polyproteins
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occurs with the help of human translation machinery.
Upon this cellular entry, the ORF-1a and ORF-1ab have
been subjected to the translation and hence the formation
of pp1a and pp1ab polyproteins. These large nonstructural
proteins are cleaved into smaller 16 nonstructural proteins
by the viral main protease (Mpro) and papain-like protease
(PLpro). This is followed by the molecular assembly and
the formation of functional viral polymerase, which is also
known as viral replicase. Assembly of several structural
proteins and encapsulation of genomic RNA end up with
plenty of viral progenies and eventually exit from the host
cell consequently spreading an infection to the other part
of the body. As the virus continues to replicate, it hits the
lungs that result in inflammation and pneumonia (Azkur,
et al. 2020; Bulut and Kato 2020; Hoffmann, et al. 2021).
The NSP1 and NSP3 take a role in the suppression of
interferon signaling and hindering host immune response
via fastening cellular degradation and hampering RNA
translation in the host (Ysrafil, et al. 2020). The NSP2 has
been shown to reduce interferon production and repressing
antiviral responses. The NSP4 and NSP6 participate in
the construction of the transmembrane scaffold protein,
especially forming double-membrane vesicles. Binary
complexes of NSP7 and NSP8 facilitate the viral RNA
processing via NSP12 (Ysrafil et al., 2020). While NSP9
contributes RNA binding protein phosphatase, NSP10,
NSP16,and NSP12 induce exonuclease (ExoN) and
2′-O-methyltransferase (2′-O-MTase) activity (Ysrafil
et al., 2020). NSP12 plays a role in RNA synthesis as an
RNA-dependent RNA-polymerase. The NSP13 as an
RNA helicase holds nucleoside triphosphatase (NTPase)
activities (Ysrafil et al., 2020). NSP14 takes a role in
viral genome proofreading (Ysrafil et al., 2020). NSP15
participates in the activities of viral endoribonuclease and
viral protease (Ysrafil et al., 2020). The NSP16 manages the
repression of melanoma differentiation-associated protein
5 (MDA5) and interference of the innate immunity
regulation (Ysrafil et al., 2020). Various studies addressed
the possibilities to target viral NSPs to develop COVID-19
specific therapeutics.
2. NSPs of SARS-CoV-2 as drug targets
2.1. NSP1: the host translation inhibitor protein of
SARS-CoV-2
SARS-CoV-2 NSP1 viral protein functions as a ribosome
modulator, preventing host translation and promoting
SARS-CoV-2 protein production (Tidu et al., 2021).
NSP1 binds to the host ribosomes and inhibits the mRNA
entry, making it one of the first proteins generated after
viral infection, thus cellular translation is inhibited. Virus
translation continues despite the presence of NSP1 on the
ribosome. The cis-acting RNA hairpin SL1 in the 5’UTR
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of SARS-CoV-2 is recently shown to be the underlying
molecular mechanism of viral evasion of NSP1 suppression
(Tidu et al., 2021).
In the late stages of the infection, SL1 is involved in the
translation of viral RNAs. As a result, treatment techniques
that target SL1 could have an impact on viral translation in
both the early and late stages of infection. It was previously
recommended that coronavirus NSP1 proteins be targeted
for the development of innovative treatment techniques
(Tidu et al., 2021). Because SL1 is found in SARS-CoV-2
viral transcripts, targeting viral translation may be possible
once small molecule or other targeting approaches are
developed.
Structure analysis of SARS-CoV-2 NSP1 demonstrates
a seven-stranded β-barrel with α-helix on one side (Clark
et al., 2021). Comparing the structure and sequence of
SARS-CoV-2 NSP1 with SARS-CoV NSP1 shows high
similarity. However, there are a few discrepancies between
the two proteins that might affect how they operate in their
distinct viral life cycles. Because of the enhanced polar
interactions between the amino acids that make up the
loops and the globular domain, some of the major loops
are in alternate conformations. Changes in the electrostatic
surface potential between the two proteins are due to amino
acid variations. Secondary structural features, such as an
extra β-strand (β5) and 310 helices, are present in SARSCoV-2 NSP1 only. Given the importance of NSP1 in the
SARS-CoV-2 virulence, these variations might explain the
higher virulence of SARS-CoV-2. Besides these important
features, there is still further research needed to develop
small molecule inhibitors that are unique to SARS-CoV-2
NSP1.
2.2. NSP2: SARS-CoV-2 the host signaling and mitochondrial biogenesis modulator
The NSP2 protein of SARS-CoV-2 is considered to have
a function in altering the host cell environment. NSP2
protein binds to host proteins PHB1 and PHB2, which
are involved in mitochondrial biogenesis and signaling
(Cornillez-Ty et al., 2009). The SARS-CoV and SARSCoV-2 NSP2 proteins share 68.3% of sequence homology
(Yoshimoto, 2020). Gupta et al. (2021) recently reported
the structure of SARS-CoV-2 NSP2 and showed that NSP2
has several contact surfaces for host proteins (Gupta et al.,
2021). These investigations provided information on how
to target these viral proteins. More study has to be done,
however, to develop SARS-CoV-2 specific small molecule
inhibitors of NSP2.
2.3. NSP3: SARS-CoV-2, a large multidomain and multifunctional protein
SARS-CoV NSP3 protein is a large multidomain protein
that includes UBL-1, AC, ADRP, SUD, UBL-2, PLpro, NAB,
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G2M, TM1-2-3-4, ZN, and Y1-2-3 domains (reviewed in
(Báez-Santos et al., 2015)). It is believed that NSP3 plays a
major role in viral replication as a central scaffold protein
of the replicase complex. Deubiquitinating/DeISGylating
domain of NSP3 is also known as PLpro domain, which
recognizes and cleaves at LXGG amino acids between NSP12, NSP2-3, and NSP3-4, at C-terminus of human ubiquitin
(UB) and interferon-stimulated gene 15 (ISG15) (Figure).
This cleavage is essential for viral replication. SARS-CoV
NSP1 protein is involved in the host mRNA degradation
and inhibition of the host mRNA translation (Reviewed

in (Báez-Santos et al., 2015)). This promotes the viral gene
expression and downregulation of the innate immune
response gene expression. SARS-CoV NSP3 interacts with
NSP4 and NSP6. Following this, NSP6 is involved in the
inhibition of autophagosome activity and delivery of viral
components to lysosomes for degradation (reviewed in
(Báez-Santos et al., 2015)). NSP3 is associated with the
reduction of proinflammatory cytokines and chemokines
endogenously. In addition, it has been shown to upregulate
CCL5, IFN-β, and CXCL10 in the cells. SARS-CoV NSP3
protein antagonizes the innate immune induction of type I

Figure. Viral invasion mechanism and role of SARS-CoV-2 NSP3 protein. NSP3 protein is involved in processing of NSP1-4 proteins via
cleavage at LNGG sites. This leads to formation of functional NSP1 (involved in host mRNA degradation), NSP2 (involved in metabolic
modulation of host cell via PHB1 and PHB2), and NSP4 (involved in assembly of viral vesicles). NSP3 with its various domains involves
DUB, DeISGlating activity, and interact with NSP4 and NSP6 to modulate innate immune response.
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interferon by blocking the phosphorylation, dimerization,
and subsequent nuclear translocation of the host IRF3
(Ratia et al., 2006) and prevent the host NF-κB signaling
thus cellular antiviral response (Ratia et al., 2006; Kocabas
and Aslan, 2015; Kocabaş and Ergin, 2016).
Comparison of SARS-CoV PLpro and SARS-CoV-2
PLpro shows 83% sequence identity with differential
substrate preference (McClain and Vabret, 2020; Shin
et al., 2020). Shin et al. (2020) showed the deISGylation
activity of SARS-CoV-2 PLpro and its involvement in the
etiology of COVID-19. It appears that inhibiting PLpro not
only prevents viral replication but also restores antiviral
immunity, making PLpro a particularly intriguing target
for future therapeutic development (reviewed in (Zhu et
al., 2021)). While SARS-CoV-2 PLpro prefers to cleave the
ISG15, SARS-CoV PLpro prefers to break ubiquitin chains
(Shin et al., 2020). In addition, SARS-CoV-2 PLpro helps
in the cleavage of ISG15 from IRF3 and inhibits type I
interferon responses following infection.
Klem et al (2020) have tested SARS-CoV PLpro
inhibitors rac3j, rac3l, and rac5c against SARS-CoV-2
PLpro (Klemm et al., 2020). In addition, rac3j, rac3l, and
rac5c partially blocked SARS-CoV-2 infection in Vero E6
cell-based assay. Kuo et al. (2021) also showed in vitro
inhibition of both Mpro and PLpro with levothyroxine
and manidipine-2HCl, which are FDA-approved medicine
(Kuo et al., 2021).
It has been recently shown that inhibition of SARSCoV-2 PLpro with GRL-0617, a naphthalene-based
inhibitor, lowers viral replication in infected cells
while maintaining the antiviral interferon pathway and
impairing the virus’s cytopathogenic impact (Freitas et al.,
2020; McClain and Vabret, 2020). A recent study further
docked GRL-0617, 3k, hypericin, cyanidin-3-O-glucoside,
and rutin into the inhibition pocket of SARS-CoV-2 PLpro
and validated their inhibitory effect in vitro (Pitsillou et
al., 2020). PLpro deubiquitinase (DUB) enzymatic assay
showed an IC50 value of 1.7 μM for GRL-0617 against
SARS-CoV-2 PLpro. Hypericin inhibited 90%, rutin
50%, and cyanidin-3-O-glucoside 42% of DUB activity of
SARS-CoV-2 -PLpro at 100 μM dose.
Osipiuk et al (2021) studied the structure of SARSCoV-2 PLpro along with the identification and validation
of seven inhibitors (Osipiuk et al., 2021). Five of these were
also validated to inhibit viral replication in cell culturebased assays. Small molecule 1 (GRL0617) inhibited
SARS-CoV-2 PLpro with an IC50 value of 2.3 μM. Small
molecules 2, 3, 4, 5, 6, and 7, which have IC50 values
ranging from 5.1 to 32.8 μM, are derivatives of GRL0617.
Small molecules 1, 4, and 7 have EC50 values ranging from
1.4 to 5.2 μM. Small molecules 2 and 3 failed to inhibit
viral replication. These findings suggest that additional
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improvement is conceivable, particularly in the case of
small molecule 5, which is a poor binder but a potent viral
inhibitor.
SARS-CoV NSP3 protein has not only include the
PLpro domain but also the AC, ADRP, SUD, UBL-2, NAB,
G2M, TM1-2-3-4, ZN, and Y1-2-3 domains, which require
further studies and knowledge to design and develop
targeted treatments.
2.4. NSP4: SARS-CoV-2 membrane remodeling and viral
vesicle assembly factor
The majority of +stranded RNA virus infection stimulates
the readjustment of host cell membranes that harbors
the formation of a viral replication complex known as
the replication and transcription complex (RTC) (Den
Boon and Ahlquist, 2010; Matsuyama, et al., 2020). This
membrane remodeling following RTC formation post virus
infection are the important sites for the viral RNA synthesis
and provide protection of newly synthesized RNA from
innate immune system components in the host (Den Boon
and Ahlquist, 2010). SARS-CoV infection has been shown
to induce the replication-associated membrane structures
which contain convoluted membranes (CMs) and doublemembrane vesicles (DMVs) as two interconnected
membrane structures (Goldsmith et al., 2004). Among all
coronavirus NSPs, the multiple transmembrane domains
have been established by NSP3, NSP4, and NSP6. Another
study showed the cellular localization of SARS-CoV
NSP3, NSP4, and NSP6 that induce DMVs formation
in the SARS-CoV infected cells through the confocal
and electron microscopy analysis (Angelini et al., 2013).
It has been intriguingly shown that the suppression of
ER export machinery by using the H89 kinase inhibitor
or by expression of a mutant Sar1[H79G] inhibited the
coronavirus replication (Hagemeijer et al., 2012). This
highlighted the significance of the early secretory pathway
in the RTC formation.
Another study conducted with PLA assay and
immunoprecipitation demonstrated the importance of
the key residues in the membrane rearrangement and the
NSP3 co-expression (Sakai et al., 2017). The NSP4 residues
between 112 and 164 are the sites where bind to NSP3.
H120 and F121 residues in NSP4 have been identified as
conserved residues between beta coronaviruses (Sakai
et al., 2017). These residues participate in viral RNA
replication with the interaction of NSP3 and employing
membrane remodeling. Mutations of H120N and F121L
resulted in the disruption of viral RNA replication
through the damage in the membrane re-arrangements.
For this reason, inhibition of NSP4 interaction with other
proteins might be utilized as a target for the development
of therapeutics. Further study, however, is required to
develop small molecules targeted to SARS-CoV-2 NSP4.
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2.5. NSP5: SARS-CoV-2 main protease (Mpro or 3CLpro)
The ORF1ab encodes the Mpro, which cleaves pp1a
and pp1ab polyproteins into 16 nonstructural proteins
(Gordon et al., 2020; Xie and Chen, 2020). Studies revealed
structural similarities and inhibitor binding modes in
MERS-CoV, SARS-CoV, and SARS-CoV-2 main proteases
(Mali, 2020; Ullrich and Nitsche, 2020). The viral protease
enzymes are vital for viral protein maturation in various
viruses because it allows the processing of proproteins after
they are translated into the host cell’s cytoplasm. Thus, viral
proteases are routinely considered as potent drug targets
to develop potential therapeutics. Blocking or reduction
of the mature viral particle generation can be achieved
by inhibiting viral proteases. To this end, many antiviral
medications that target proteases such as HIV-1 protease
and HCV protease have been developed and approved by
FDA (Wang et al., 2015). As a result, developing antiviral
medicines that inhibit SARS-CoV-2 Mpro might be useful
in the clinic (reviewed in (Mengist et al., 2021)).
Several small molecules exhibited efficient binding and
inhibition of SARS-CoV-2 Mpro as they were validated
by in vitro assays, antiviral activity towards SARS-CoV-2,
and in vivo infected mice investigations (Rathnayake et
al., 2020; Riva, et al., 2020). The structure of SARS-CoV-2
Mpro in association with various potential small molecule
inhibitors such as peptidomimetic α-ketoamide inhibitors
was also recently shown (Zhang et al., 2020). Dai et al
(2020) developed aldehyde-based small molecules 11a and
11b that inhibited SARSCoV-2 Mpro up to 100 percent at 1
μM (Dai et al., 2020). These two small molecules were also
shown to prevent SARS-CoV-2 infection (Dai et al., 2020).
The scientists improved a previously proposed inhibitor
(11r to 13a), which is resulting in longer plasma stability
(Mengist et al., 2020; Zhang et al., 2020). Zhang et al. (2020)
reported compounds 11r and 13a having IC50 values of
0.18 μM and 2.39 for SARS-CoV-2 Mpro, respectively
(Zhan, et al., 2020). Small molecules 13a and 13b showed
selective binding to SARSCoV-2 Mpro, reduction of
enzyme activity, and viral infectivity. Compound 13b had
an IC50 value of 0.67 μM against SARS-CoV-2 Mpro and
an EC50 value of around 5 μM when tested in vitro with
SARS-CoV-2 assays in human Calu3 cells (reviewed in
(Sharma et al., 2020)).
N3 interacted with several hydrogen bonds and acted
as an irreversible Michael acceptor inhibitor of SARSCoV-2 Mpro (Griffin, 2020; Jin et al., 2020). Another
research determined the structure of N3 binding into the
SARS-CoV-2 Mpro substrate-binding pocket (Jin, et al.
2020). Infected Vero cells with SARS-CoV-2 demonstrated
high antiviral activity of N3 at 10 μM. Jin et al. (2020) also
revealed that carmofur binds to the SARS-CoV-2 Mpro
Cys145 residue and inhibits viral replication (Jin et al.,

2020). Ebselen, an antiinflammatory and antioxidant, has
also been shown to bind to the active site of SARS-CoV-2
Mpro and has significant antiviral activity, thus, it has been
suggested to be useful in treating COVID-19 (Jin et al.,
2020; Sies and Parnham, 2020).
Su et al. (2020) identified natural molecules originating
from Chinese traditional medicine, baicalin, and baicalein
as new inhibitors of the SARS-CoV-2 Mpro with antiviral
activity in Vero E6 cells, with IC50 values of 6.4 and 0.9
μM respectively (Su et al., 2020). They demonstrated
that baicalein can inhibit SARS-CoV-2 Mpro through
hydrogen bonds between baicalein and Leu141/Gly143
and Ser144/His163 residues (Su et al., 2020).
Vuong et al. (2020) utilized a prodrug approach to
develop an SARS-CoV-2 Mpro inhibitor. They have shown
conversion of GC376 after forming a covalent bond with
Cys145 into GC373 in SARS-CoV-2 Mpro (Vuong et al.,
2021; Vuong et al., 2020). Additional hydrogen bonds
were also reported between SARS-CoV-2 Mpro catalytic
region and GC373 indicating a high binding affinity and
inhibition as low as nano-molar level between enzyme
and ligand (Liu et al., 2021; Sharun et al., 2021). Iketani
et al. (2021) have reported molecules namely compound
4, GC376, and MAC-5576 as inhibitors of SARS-CoV-2
main protease (Iketani et al., 2021). Compound 4 and
GC376 showed IC50 values of 151 nM and 160 nM against
SARS-CoV-2 Mpro, respectively. Further studies showed
that compound 4 and GC376 could inhibit SARS-CoV-2
viral replication in vitro at EC50 values of 2.8 μM and 2.1
μM, respectively. While MAC-5576 had the lowest IC50
value of 81 nM against SARS-CoV-2 Mpro, it was not
capable of inhibiting SARS-CoV-2 viral replication. Ma et
al. (2020) also showed that GC-376 along with boceprevir,
and calpain inhibitors II and XII as potent Mpro inhibitors
with antiviral activity (EC50 as low as 0.49 μM) (Ma et al.,
2020).
Riva et al. (2020) performed a drug repurposing
screening to identify potent SARS-CoV-2 inhibitors
(Riva et al., 2020). Intriguingly, several cysteine protease
inhibitors MDL-28170, Z LVG CHN2, VBY-825, and
ONO 5334 were shown to pose antiviral activity suggesting
that targeting viral proteases is a plausible strategy to
develop COVID-19 therapeutics. Rathnayake et al (2020)
studied 6e and 7j in SARS-CoV-2 infected Vero E6 cells to
demonstrate its antiviral activity (Rathnayake et al., 2020).
The scientists also demonstrated that these Mpro inhibitors
can enhance the survival of coronavirus-infected mice
(Rathnayake et al., 2020).
Coelho et al. (2020) employed screening to find
possible SARS-CoV-2 Mpro inhibitors (Coelho et al.,
2020). The study allowed identifying and validating
thirteen potential inhibitors of recombinant SARS-
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CoV-2 Mpro with IC50 values ranging from 0.2–23 μM.
Thimerosal, phenylmercuric acetate, and Evans blue were
the most potent inhibitors with IC50 values of less than 1
μM. Glaab et al. (2021) selected 95 small molecules after
in silico studies to determine in vitro SARS-CoV-2 Mpro
inhibitory activity (Glaab et al., 2021). Two compounds
rottlerin and M-8524 (CID 46897844) showed IC50 values
of 37 μM and 31 μM, respectively.
Qiao et al. (2021) reported 32 new bicycloproline
based SARS-CoV-2 Mpro inhibitors with IC50 values
ranging 7.6 to 748.5 nM (Qiao, et al. 2021). Further
studies with compounds MI-09 (EC50 = 0.86–1.2 μM)
and MI-30 (EC50 = 0.54–1.1uM) showed robust antiviral
activity in vitro and in vivo. In addition, MI-09 and MI30 reduced lung viral load and lesions in a SARS-CoV-2
infected hACE2 transgenic animal model. These findings
suggest that administering MI-09 or MI-30 may effectively
limit SARS-CoV-2 replication and mitigate SARS-CoV-2
induced lung lesions, which are establishing a major step
in the development of anti–SARS-CoV-2 medicines.
Previously identified HCV NS3/4A protease inhibitors
have been proposed to bind to SARS-CoV-2 Mpro with
an antiviral activity (reviewed in (Mengist et al., 2021)). A
number of ligand-SARS-CoV-2 Mpro structure analyses
reported different compounds including N3 (PDB:6LU7),
11a (PDB:6LZE), 11b(PDB:6M0K), X77 (PDB:6W63), 13b
(PDB:6Y2G), Baicalein (PDB:6M2N), Boceprevir (PDB:
7K40), Narlaprevir (PDB:7JYC), Telaprevir (PDB:7K6D),
Carmofur (PDB:7BUY), GC373 (PDB:6WTK), GC376
(PDB:6WTT), biotin-PEG(4)-Abu-Tle-Leu-Gln-vinylsulfone
(PDB:6Z2E), x0397 (PDB:5RGI), X2754 (PDB:5RHF), and
X2705 (PDB: 5RH7).
In short, these small molecule inhibitors blocking the
activity of NSP5 showed that targeting viral main protease
is a plausible strategy to achieve the development of SARSCoV-2 specific therapeutics.
2.6. NSP6: SARS-CoV-2 autophagosome modulator
Several NSPs are collected into replication complexes on
the ER cytoplasmic region. Assembly of replicase proteins
and genome replication are concurrently associated
with the formation of DMVs and autophagy activation.
Although autophagy machinery-mediated degradation
can promote the innate defense mechanism against virus
infection, autophagosomes of (+) strand RNA viruses can
also provoke the infection by enabling the replicase proteins
assembly (Cottam et al., 2014). As a cellular response,
autophagy constitutes autophagosomes that transport
long-lived proteins and damaged cellular proteins to
lysosomes for their degradation. This also supplies a shortterm obtainment of amino acids when starvation happens
(Wang and Klionsky, 2003). Autophagy with this potential
to degrade the massive quantities of cytoplasm enables
host cells to fight intracellular pathogens and provides
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the presentation of invader components to the immune
system (Levine, 2005).
The protein NSP6 of infectious bronchitis virus,
mouse hepatitis virus, avian coronavirus, and SARS has
been shown to induce autophagy. Since it has multiple
membrane-spanning domains and located in the ER,
NSP4 produces autophagosomes from ER (Cottam et
al., 2011). A study conducted with viral NSP6 has been
also shown that NSP6 coronavirus protein restricts the
expansion of autophagosomes whether generated directly
via NSP6 protein or indirectly in response to starvation
or small molecule Torin1 mediated inhibition of mTOR
pathway signaling (Cottam et al., 2014). It is unclear why
coronaviruses restrict the expansion of autophagosomes
even if the infection with coronavirus has been stated
to activate autophagy. More work is needed for the
NSP3, NSP4, and NSP6 sub-complex interaction in
the formation of DMVs as well as the cooperation with
autophagy machinery. Targeting autophagy or the mTOR
signaling pathway by using small molecules could provide
more understanding for the design of viral therapeutics
as well as broadening the reservoir of antivirals. Studies
also suggest that SARS-CoV-2 NSP6 could be directly
targeted by small molecules (Pandey, et al. 2020). Analysis
of haloperidol and dextromethorphan, especially, shows
that they bind tightly to NSP6 and cause alterations in its
structure and dynamics relevant to their distinct modes
of action. However, further studies are still needed for the
discovery and development of SARS-CoV-2 NSP6 specific
inhibitors.
2.7. NSP7, NSP8, and NSP12: SARS-CoV-2 RNA-dependent RNA polymerase complex
The genome of (+) stranded RNA viruses possesses
RNA-dependent RNA polymerase (RdRp) to carry out
viral genome replication (Paul and Wimmer, 2015).
Upon the infection into host cells, the replication of viral
RNA cannot launch until the polymerase is translated
directly from genomic RNA of (+) stranded RNA viruses.
Therefore, the activity of RdRp plays a critical role in the
synthesis of SARS-CoV-2 RNA. NSP7-NSP8 complex has
been stated to enhance the RNA polymerase activity in a
primer-dependent manner (Te Velthuis et al,. 2012). In
addition to NSP12 protein as a presumed main RdRp, the
polymerase activity assays and NSP8 mutagenesis studies
suggested this unique NSP7 and NSP8 complex is most
likely to be another SARS-CoV polymerase that boosts the
RdRp activity (Te Velthuis, et al. 2012).
The NSP8 protein has been reported in the activity of
oligonucleotide synthesis in a template-dependent manner
(Imbert et al., 2006). This protein binds to a specific short
sequence in the ssRNA genome of coronavirus and is able
to perform de novo RNA synthesis up to six nucleotides.
Subsequently, this can be utilized as a primer for the RdRp
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synthesis with low fidelity indicating the similarity with
DNA-dependent RNA primase (Imbert et al., 2006). CoVs
exhibit this specialized NSP8 RNA enzyme activity for the
primer synthesis known as primase. It has been stated that
NSP8 protein could be an interesting target against CoVs
and inhibition of NSP8 was determined by using GTP
analogs including 3’-dGTP, ddGTP, and 20-O-methylGTP (Imbert et al., 2006). While 3’-dGTP showed efficient
inhibition of NSP8 RdRp, ddGTP and 20-O-methylGTP were found as weak inhibitors. Alanine-scanning
mutagenesis indicated that RdRp activity of NSP8 was
aborted or seriously diminished with K58A, R75A, K82A,
and S85A mutations.
Analysis of replication complex including NSP7
and NSP8 showed that SARS-CoV-2 NSP8 undergoes
conformational changes and interacts with the departing
RNA. A model for the transition from primase to
polymerase complex sheds light on the mechanism of
remdesivir incorporation and delayed chain termination
in viral RNA replication (Wang, et al. 2020). In addition,
the GST-pull down assays indicated the interaction of
NSP8 with NSP12 (Imbert et al., 2006). Thus, NSP8/
NSP12 interaction was also proposed to be targeted to
develop inhibitors of this complex, which is important in
viral replication (Mutlu et al., 2020). The NSP12–NSP8
complex of SARS-CoV-2 was targeted utilizing a structurebased and computer-aided drug design strategy (Mutlu
et al., 2020). Despite the partial mobility of the RX-3117
and Nebivolol ligands in the binding cavity, they were not
dislodged from the binding pocket after 100 nanoseconds
suggesting that they could potentially inhibit NSP12–
NSP8 complex of SARS-CoV-2 and could be further
validated in order to pave the way for new COVID-19
treatment approaches. These studies provided an insight
into how to target these viral proteins. Further research is
needed, however, to develop SARS-CoV-2 specific NSP7
and NSP8 small molecule inhibitors.
RdRp is a key catalytic component for RNA synthesizing
machinery. In all (+) strand RNA viruses, RdRp produces
negative-strand RNA, new genome elements, and mostly
subgenomic messenger RNAs. In coronaviruses, RdRp
catalyzes the viral RNA synthesis and produces negativestrand RNA starting from 3’-poly-A-tail by using (+)
stranded RNA strand as a template. In order to initiate
the genomic RNA synthesis, the viral RdRps operate
two essentially different mechanisms which are de novo
known as primer independent RNA synthesis and primer
dependent RNA synthesis (Van Dijk et al., 2004). During
de novo synthesis, the first nucleotide 3’hydroxyl group
acts as a primer, and the second nucleotide 5’-phosphate
group is added through the formation of phosphodiester
bonds. In the case of primer-dependent RNA synthesis, the
initiation of new RNA strand synthesis depends on either

an oligonucleotide or a protein primer. SARS-CoV NSP12
acts as a canonical RdRp that catalyzes the viral RNA
synthesis and plays a crucial role in the viral replication
and transcription with the assistance of SARS-CoV NSP7
and NSP8 (Subissi et al., 2014a; Subissi et al., 2014b). Thus,
the SARS-CoV-2 polymerase complex is constituted with
NSP12 RdRp and NSP7/NSP8 cofactors (Gao et al., 2020;
Peng et al., 2020). It has been reported that the activity of
SARS-CoV NSP12 is highly augmented upon the binding
of the NSP7/NSP8 complex (Subissi et al., 2014a; Subissi
et al., 2014b).
The development of in vitro RdRP assays, which allow
screening and identification of small molecules, are crucial
for therapeutics targeting viral RNA synthesis (Kocabas
et al., 2015). Various methods have been proposed and
reported to function in the identification of various virus
RdRp inhibitors. Nucleotide analogs that target viral RNA
polymerase have been shown to be a promising antiviral
medication (Lu et al., 2020). Lu et al. (2020) developed a
nonradioactive primer extension assay to evaluate SARSCoV-2 RdRp activity as well as potential inhibitors (Lu et
al., 2020). They have shown that adding some remdesivirTP to the reaction mix triggered chain termination. In
addition, they have reported that 2’-C-methyl-GTP can be
easily integrated into RNA. 2’-C-methyl-GTP derivative
demonstrates efficacy to treat SARS-CoV-2 infection (Lu
et al., 2020).
Remdesivir is currently one of the FDA-approved drugs
for COVID-19 treatment. Kokic et al. (2021) showed that
Remdesivir’s active form operates as a nucleoside analog to
inhibit SARS-CoV-2 RdRp (Kokic et al., 2021). Remdesivir
is incorporated into the developing RNA product by the
RdRp, which is allowing three additional nucleotides to be
added before RNA synthesis stops. The structural analysis
of the remdesivir-stalled state may hinder proofreading
by the viral 3-exonuclease, suggesting a potent mode
of inhibition by next-generation therapeutics targeting
SARS-CoV-2 RdRp. Ribavirin is a ribonucleoside analog
with a broad range of antiviral activity. Ribavirin antiviral
mechanisms are debated and it is stated that it disrupts
the viral RNA replication in the host or it can increase
the immune response. A study showed that Ribavirin at
a concentration of 109.50 μM and favipiravir at 61.88 μM
caused 50% CPE in Vero cells infected with SARS-CoV-2
(Wang et al., 2020). Favipiravir was also used in the fight
against COVID-19. Favipiravir reduces SARS-CoV-2 RNA
replication (Naydenova, et al. 2021). The structure analysis
indicates that favipiravir binds to the catalytic location of
SARS-CoV-2 RdRp with a low rate of incorporation into
the RNA primer strand (Naydenova et al., 2021).
Sofosbuvir (GS‐7977; formerly PSI‐7977) is an
FDA-approved hepatitis C virus (HCV) inhibitor,
which is developed by Gilead (Rodriguez-Torres et al.,
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2013). This drug has been shown as the first to be used
safely and to be effective with no need for the usage of
interferon. The sofosbuvir with velpatasvir is approved as
EPCLUSA and tested in HCV (Greig, 2016). HCV RdRp
shows structural homology and replication mechanism
similar to SARS-CoV-2 RdRp. A study conducted with
polymerase extension assays stated that sofosbuvir active
triphosphate form inhibited SARS-CoV-2 RdRp (Chien
et al., 2020). Similarly, the other FDA-approved antivirals,
which are Alovudine as an HIV/AIDS drug and Tenofovir
alafenamide as an HIV/hepatitis B drug were tested for
the inhibition of SARS-CoV-2 RdRp (Chien et al., 2020)
have been shown to block the SARS-CoV-2 polymerase
extension.
Galidesivir (BCX4430) is a synthetic adenosine
analogue and it has been shown to inhibit viral RNA
polymerase in various RNA viruses including SARSCoV and Mers-CoV (Warren et al., 2014). The role of
BCX4430 in the inhibition of viral polymerase is stated as
a nonobligate RNA chain terminator (Warren et al., 2014).
The inhibitory activity of BCX4430 against SARS‐CoV
was stated as 57.7 μM EC50 value and CC50 > 296 μM in
HeLa cells by using high‐content image assays (Warren, et
al., 2014; Pruijssers and Denison, 2019).
EIDD‐1931 is the ribonucleoside analog β‐D‐N4‐
hydroxycytidine. Several studies demonstrated the
inhibitory function against influenza virus, Ebola, and
several CoVs with the broad range antiviral spectrum
activity (Agostini et al., 2019; Sheahan et al., 2020). The
inhibitory effect of NHC against SARS-CoV-2 has been
shown as EC50 of 0.3 μM in Vero cells and EC50 of 0.08
μM in Calu‐3 cells (Sheahan et al., 2020). EIDD‐2801 is
an orally bioavailable NHC prodrug. EIDD‐2801 showed
enhanced pulmonary function and diminished viral load
in mice infected with SARS‐CoV or MERS‐CoV (Sheahan
et al., 2020).
Recently, the stable nitroxide TEMPOL has been
reported with a strong inhibitory effect on the RdRp
activity of SARS-CoV-2 (Maio et al., 2021). NSP12 RdRp
has been found to cooperate with two iron-sulfur (Fe-S)
metal cofactors in the site of zinc centers. TEMPOL oxides
Fe-S clusters and inhibits SARS-CoV-2 RdRp through
the direct interaction within Fe-S clusters in RdRp that
causes their degradation. In addition, it has been stated
that TEMPOL displayed robust antiviral activity in Vero
E6 cells infected with SARS-CoV-2 (Maio et al., 2021).
This study indicates the potentiality of TEMPOL and
other alternative stable nitroxides for the development of
therapeutics against SARS-CoV-2.
These studies, overall, suggest the potential of
nucleoside analogues as polymerase inhibitors for the
development of COVID-19 therapeutics.
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2.8. NSP9: SARS-CoV-2 RNA replicase
The NSP9 is thought to participate in viral replication
and pathogenicity. The structure of SARS-CoV-2 NSP9
was defined with unique fold characteristics as well as the
dimerization interface. NSP9 binds to RNA through this
distinctive fold feature of coronaviruses harboring the
GxxxG interaction motif (Littler et al., 2020). Thus, the
role of NSP9 was determined in the RNA/DNA binding
activity. SARS-CoV NSP9 is able to form a dimer at the
GXXXG motif. This dimerization of NSP9 has been shown
as a critical and required step for the SARS-CoV viral
replication, however, it is not necessary for RNA binding.
In addition, in silico studies suggest that SARS-CoV-2
NSP9 could be targeted as shown with the identification of
a potent inhibition pocket (Farias et al., 2021). In addition,
known antivirals have been proposed to interact with this
pocket and could decrease the flexibility of the monomer
compared to the dimer. However, there are currently no
known or validated small molecule inhibitors targeted to
SARS-CoV-2 NSP9 protein.
2.9. NSP10 and NSP16: SARS-CoV-2’s 2′-O-ribose methyltransferase complex
The eukaryotic mRNAs have unique features with a
5’ methylated cap structure that is needed for mRNA
stability and translation process. All viruses utilize host
cell ribosomes for their protein translation and CoVs
have been equipped with such a cap structure for their
viral RNA. It has been demonstrated that cap structure
with ribose 2′-O-methylation provides a viral escape
from the recognition of the host’s innate immune system
(Schoggins and Rice, 2011). SARS-CoVs encode the
2′-O-methyltransferase and it consists of two subunits
which are the NSP16 catalytic subunit and NSP10
stimulatory subunit (Chen et al., 2011). This 2′-O-MTase
activity is unique for CoVs compared to other viruses or
hosts (Chen et al., 2011). It has been shown that SARS-CoV
NSP10 is required for the NSP16 enzyme activity (Chen et
al., 2011). NSP10 stimulates NSP16 to attach capped RNA
and the methyl donor S-adenosyl-L-methionine (SAM)
(Chen, et al. 2011).
The function of the NSP10/16 complex is to catalyze
the methylation of the RNA cap of the virus at the ribose
2′-O position. By methylation, the viral RNA cap-0
structure which is featured as 7MeGpppA… converted
into 7MeGpppA2′-O-Me… cap-1 structure. This provides
an advantage for mimicking cellular mRNAs and hence
tricking the host immunity from viral RNAs recognition
(Chen et al., 2011; Decroly et al., 2011).
The SARS-CoV-2 NSP10/NSP16 2′-O-MTase has
been characterized at the atomic level. It has been stated
that SAM analogs SIN could target the conserved SAM
binding pocket within the NSP10/NSP16 complex
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(Lin, et al. 2020). Studies suggest that the SARS-CoV-2
NSP10-NSP16 complex is druggable as much as other
methyltransferases (reviewed in (Chang and Chen, 2021)).
However, there is an unmet demand for an improved assay
for small molecule screening.
Yazi et al (2021) have recently reported a radioactivitybased assay for the methyltransferase activity of the
NSP10-NSP16 complex, which is suitable for a 384-well
plate (Khalili Yazdi et al., 2021). In addition, Perveen et al.
(2021) reported a RNA displacement assay to target and
analyze the activity of the SARS-CoV-2 NSP10-NSP16
complex (Perveen et al., 2021). They confirmed their assay
with the purified NSP10-NSP16 complex with binding
to the methyl donor SAM. In addition, they were able to
observe the reaction product S-adenosyl-l-homocysteine
(SAH) and showed inhibition of enzymatic assay with a
common methyltransferase inhibitor, sinefungin. This
was followed by a screening of thousands of drug-like
compounds to determine RNA-competitive inhibitors
in the NSP10-NSP16 complex in the hopes of finding
COVID-19 treatments. Although they have determined
three compounds with concentration-dependent
inhibition, they failed to show any binding when tested by
isothermal titration calorimetry.
2.10. NSP11: SARS-CoV-2, a minor cleavage product
SARS-CoV-2 NSP11 is a minor product of cleavage
that comes from the Mpro pp1a processing (Gadhave
et al., 2020; Gadhave et al., 2021). Its whole sequence of
amino acids is SADAQSFLNGFAV. There has been no
description of an independent NSP11 function. However,
a recent study highlighted that SARS-CoV-2 NSP11
protein is inherently disordered and forms a helical shape
in appropriate conditions. In comparison to neutral and
anionic lipids, it demonstrates a great affinity for the
SDS micelles and is ready to undergo conformational
transformation. Intriguingly, Gadhave et al., (2020) suggest
that SARS-CoV-2 NSP11 can operate in the affinity and
contact between the cytosolic host membranes (Gadhave
et al., 2020; Gadhave et al., 2021).
2.11. NSP13: SARS-CoV-2’s helicase
SARS-CoV-2 NSP13 is a helicase, thereby it uses ATP
hydrolysis to unwind duplex DNA and RNA with a 5′
single-stranded tail in the 5′–3′ direction (Reviewed in
(Suryawanshi, et al. 2021)). SARS-CoV-2 NSP13 along
with other proteins were also shown to inhibit interferon
production and nuclear localization of IRF3 (Yuen, et al.
2020). In addition, SARS-CoV-2 NSP13 along with NSP1
inhibited caspase-1 activity and IL-1 production caused by
the NLRP3 inflammasome (Kim, et al. 2021).
White et al. (2020) studied SARS-CoV-2 NSP13
helicase and performed an in silico screening followed

by in vitro validation of two-hit compounds (White et
al., 2020). Their targeting strategy involved docking into
the ATP-binding site of the NSP3 helicase homology
model. Lumacaftor and Cepharanthine were among the 10
tested compounds that showed IC50 values of 0.3 and 0.4
mM against SARS-CoV-2 in ATPase assay, respectively.
Intriguingly, Cepharanthine was reported as an inhibitor
of SARS-CoV suggesting that it may also inhibit SARSCoV-2 viral replication (Zhang et al., 2005).
2.12. NSP14: SARS-CoV-2 3′ to 5′ exoribonuclease and
(guanine-N7)-methyltransferase
SARS-CoV-2 NSP14 mainly has a 3′ to 5′ exoribonuclease
activity that removes mismatches that occur during viral
genome replication. It interacts with NSP7, 8, 10, and 12
(reviewed in (Suryawanshi et al., 2021)). SARS-CoV-2
NSP14 has also a (guanine-N7)-methyltransferase (N7MTase) activity that prevents newly generated viral RNA
from being degraded. The presence of this exoribonuclease
domain is required for its capping function, although the
domain’s enzymatic activity was shown to be not necessary.
Renata et al. (2021) used a Py-FLINT assay to test
about 7000 compounds for inhibition of SARS-CoV-2
NSP14 N7-methyltransferase (Kasprzyk et al., 2021).
Pyridostatin, which was among the 33 most potent NSP14
N7-methyltransferase inhibitors, had an IC50 value of 3.19
μM and reduced viral replication with an EC50 of 3.58 μM
and selectivity index of 16.6. Other NSP14 N7-MTase
inhibitors Gastrodenol, theaflavin-3,3’-di-O-gallate,
Reactive Blue 2, and Evans Blue demonstrated antiviral
activity with IC50 values of 40.1, 33.2, 16.3, and 30.9 μM,
respectively. In addition, Canal et al. (2021) tested about
five thousand compounds and determined patulin and
aurintricarboxylic acid nsp14 exoribonuclease inhibitors
with antiviral activity in a Vero infection model (Canal,
et al. 2021).
Basier et al. (2021) tested over 5000 compounds in
vitro by homologous time-resolved fluorescence (HTRF)
assay and reported four potent SARS-CoV-2 NSP14 RNA
cap methyltransferase inhibitors with an antiviral activity
based on the SARS-CoV-2 infection model (Basier, et al.
2021). PF-03882845, trifluperidol, inauhzin, lomeguatrib,
and inhibited SARS-CoV-2 NSP14 with HTRF50 values
of 1.1, 12.9, 23.0, and 53.8 μM, respectively. PF-03882845,
inauhzin, and trifluperidol demonstrated antiviral EC50 of
10.97, 14.9, and 12.96 μM respectively. Lomeguatrib had
EC50 about 60 μM and showed cytotoxicity. In addition,
these compounds demonstrated synergy when combined
with remdesivir to lower IC50 against SARS-CoV-2 in
vitro.
These findings suggest that targeting SARS-CoV-2
NSP14 is a plausible strategy in the development of
sensible COVID-19 treatments.
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2.13. NSP15: SARS-CoV-2 endoribonuclease
SARS-CoV-2 NSP15 demonstrates a uridine-specific and
Mn(2+)-dependent endoribonuclease activity that reduces
viral dsRNA sensing by host dsRNA sensors (Kim et al.,
2020). Because of the structural likenesses, inhibitors of
SARS-CoV NSP15 have a strong possibility of inhibiting
the SARS-CoV-2 NSP15. Kim et al. (2021) recently
developed a synthetic oligonucleotide substrate cleaved by
SARS-CoV-2 NSP15 that allowed to identify tipiracil as a
potent inhibitor of SARS-CoV-2 NSP15 endoribonuclease
activity by binding to uridine binding site (Kim et al., 2020;
Kim, et al., 2021). This is associated with a 50% reduction
at 7.5 μM tipiracil treatment albeit with modest antiviral
activity (EC50 of >50 μM) in vitro.
3. Conclusions and discussion
This study addressed the validated inhibitors that target
SARS-CoV-2 NPSs and their antiviral efficacy as a possible
COVID-19 candidate therapeutic. Pharmaceutical
repurposing and design of novel chemical entities in need
to treat COIVID-19 play important roles in the rapid
identification of effective medicines. As a result, resolving
3D structures as well as SARS-CoV-2 NSP specific
enzymatic tests are often required for the discovery of
COVID-19 specific inhibitors.
The ideal inhibitors should have high specificity
for the target and be effective as an antiviral in vitro as
well as in vivo after being administered to SARS-CoV-2
animal models. This also requires inhibitors to possess a
reasonable plasma half-life. Although many inhibitors
described so far by in silico studies have high binding
affinity to studied SARS-CoV-2 NSPs, they often lack
validation by in vitro SARS-CoV-2 NSP specific enzymatic
assays or lack antiviral activity. Thus, we highlighted only
and focused on the validated inhibitors of SARS-CoV-2
NSPs in relation to their pharmaceutical mechanism of
action (Table). In addition, we have summarized if they
had any antiviral activity, in vivo efficacy against SARSCoV-2 infections as well as their bioavailability and
pharmacokinetics if the information is provided.
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Studies on SARS-CoV-2 biology concerning NSP
complexes show that the majority of NSPs could be
targeted by small molecules and they are druggable. For
many of the NSPs, there have been reports or attempts
to develop assays that could allow the screening of a
large number of small molecules. SARS-CoV-2 NSP3,
NSP5, NSP12, NSP13, and NSP15 have been shown to
be inhibited at least by one small molecule in vitro in
respective enzymatic assays as well as in vitro antiviral
assays (Table). In addition, several inhibitors targeting
SARS-CoV-2 NSP5 Mpro have been shown to be effective
in vivo in SARS-CoV-2 infection models. Inhibitors of
NSP3 or NSP5 proteases might possibly decrease the
activity of important human proteases since viral proteases
and human host proteases have comparable substrates and
hydrolysis processes. Thus, it is critical to examine the
selectivity of inhibitors to NSP3 or NSP5 proteases during
hit selection, lead optimization, and drug development
to assure specificity and selectivity of the final medicines
against SARS-CoV-2 NSPs.
In summary, a tremendous effort done by scientists
globally in less than a year showed that several viral NSPs
are druggable with validated small molecules that are
efficacious in vitro, in vivo, and with a reasonable plasma
half-life. Further studies in drug development soon could
allow the generation of COVID-19 specific medicines
by blocking key enzymes involved in pathogenesis,
replication, and infection of SARS-CoV-2. However, more
research is needed to develop specific inhibitors for the
majority of NSPs.
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Table. Current status of validated small molecule inhibitors of SARS-CoV-2 NSPs.
SARS-CoV-2
protein

Validated inhibitors with IC50 values based
on the in vitro enzymatic assays

NSP1

Not reported

Validated inhibitors with EC50 values based
on the in vitro SARS-CoV-2 antiviral assays
or in vivo efficacy
Not reported

NSP2

Not reported

Not reported

NSP3

Rac3j (1.4 μM), rac3k (1.15 μM), rac5c (0.81
μM), Levothyroxine (15.3. μM), manidipine2HCl (14.2 μM), maprotiline (9.7 μM),
reserpine (5.7 μM), loperamide (33.5 μM),
proanthocyanidin (2.4 μM), GRL-0617 and
its derivatives 4 and 7 (2.3–32.8 μM),
Hypericin (90% inhibition at 100 μM).

Loperamide (11.4 μM), manidipine-2HCl
(14.5 μM), maprotiline (9.3 μM),
(Klemm et al., 2020; Kuo
Levothyroxine (7.0 μM), proanthocyanidin et al., 2021; Osipiuk et al.,
(2.5 μM), and reserpine (6.6 μM), GRL-0617 2021; Pitsillou et al., 2020)
and its derivatives 4 and 7 (1.4 to 5.2 μM).

NSP4

Not reported

Not reported

-

NSP5

11a (0.053 μM), 11b (0.040 μM), 11r
(0.18 μM), 13a (2.39 μM), 13b (0.67μM),
Thimerosal (0.6 μM), phenylmercuric acetate
(0.4 μM), Evans blue (0.2 μM), Tannic acid
(2.1 μM), Hematoporphyrin (3.9 μM),
baicalin (6.41 μM), baicalein (0.94 μM),
rottlerin (37 μM), M-8524 (CID46897844, 31
μM), MI-09 (0.015 μM), MI-30 (0.017 μM),
compound 4 (0.15 μM), GC376 (0.16 μM),
MAC-5576 (0.08 μM), Cinanserin (125 μM),
N3 (N.A.), Disulfiram (9.35 μM), Ebselen
(0.67 μM), Carmofur (1.82 μM), Tideglusib
(1.55 μM), PX-12 (21.39 μM), Shikonin
(15.75 μM).

11a (0.53 μM), 11b (0.72 μM), 13b (4–5 μM),
baicalin (10.27 μM), baicalein (1.69 μM), MI09 (0.86–1.2 μM in vitro and in vivo antiviral
efficacy), MI-30 (0.54–1.1 μM in vitro and
in vivo antiviral efficacy), compound 4 (2.88
μM), GC376 (2.19 μM), Cinanserin (20.6
μM), N3 (16.77 μM), Ebselen (4.67 μM)

(Coelho et al., 2020; Dai
et al., 2020; Glaab et al.,
2021; Iketani et al., 2021;
Jin et al., 2020; Qiao et
al., 2021; Su et al., 2020;
Vuong et al., 2021; Zhang
et al., 2020)

NSP6

Not reported

Not reported

-

NSP7

Not reported (see NPS12)

Not reported (see NPS12)

-

NSP8

Not reported (see NPS12)

Not reported (see NPS12)

-

NSP9

Not reported

Not reported

-

NSP10

Not reported

Not reported

-

NSP11

Not reported

Not reported

NSP12

NHC, Remdesivir, Favipiravir, 2’-C-methylGTP, nitroxide TEMPOL, Sofosbuvir,
Tenofovir alafenamide

NSP13

Lumacaftor (0.3 mM) and Cepharanthine
and (0.4 mM)

NSP14

Pyridostatin (3.19 μM and selectivity
index of 16.6), PF-03882845 (1.1 μM),
Trifluperidol (12.9 μM), Inauhzin (23.0 μM),
Lomeguatrib (53.8 μM), Gastrodenol (1.08
μM), theaflavin-3,3’-di-O-gallate (1.36 μM)
, Reactive Blue 2 (4.12 μM), Evans Blue (4.84
μM), patulin (1.8 μM) and aurintricarboxylic
acid (10.3 μM)

Pyridostatin (3.58 μM), PF-03882845 (10.97
μM), Inauhzin (14.9 μM), Trifluperidol
(Basier et al., 2021; Canal
(12.96 μM), Lomeguatrib (~ 60 μM with
et al., 2021; Kasprzyk et
cytotoxicity), Reactive Blue 2 (16.3 μM)
al., 2021)
Gastrodenol (40.1 μM), theaflavin-3,3’-di-Ogallate (33.2 μM), Evans Blue (30.9 μM).

NSP15

Tipiracil (~ 7.5 μM)

Tipiracil (> 50 μM)

(Kim et al., 2021)

NSP16

Not reported

Not reported

-

References
-

(Chien et al., 2020; Lu
NHC (0.08–0.3 μM), Remdesivir (109.5 μM),
et al., 2020; Maio et al.,
Favipiravir (61.8 μM), 2’-C-methyl-GTP
2021; Sheahan et al., 2020)
derivative, nitroxide TEMPOL
(Wang et al., 2020)
Cepharanthine was reported as an inhibitor
of SARS-coV1. Not tested for SARS-CoV-2 (White et al., 2020)
viral replication yet.

479

KOCABAŞ and USLU / Turk J Biol
References
Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X et al. (2019).
Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a
proofreading-intact coronavirus with a high genetic barrier to
resistance. Journal of Virology 93.

Cottam EM, Maier HJ, Manifava M, Vaux LC, ChandraSchoenfelder P et al. (2011). Coronavirus nsp6 proteins
generate autophagosomes from the endoplasmic reticulum via
an omegasome intermediate. Autophagy 7: 1335-1347.

Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ,
Moscona A (2013). Severe acute respiratory syndrome
coronavirus nonstructural proteins 3, 4, and 6 induce doublemembrane vesicles. mBio 4.

Cottam EM, Whelband MC, Wileman T (2014). Coronavirus NSP6
restricts autophagosome expansion. Autophagy 10: 1426-1441.

Azkur AK, Akdis M, Azkur D, Sokolowska M, Veen W et al. (2020).
Immune response to SARS‐CoV‐2 and mechanisms of
immunopathological changes in COVID‐19. Allergy 75: 15641581.
Báez-Santos YM, St. John SE, Mesecar AD (2015). The SARScoronavirus papain-like protease: structure, function and
inhibition by designed antiviral compounds. Antiviral
Research 115: 21-38.
Basier C, Basu S, Beale R, Canal B, Cowling VH et al. (2021).
Identification of SARS-CoV-2 antiviral compounds by
screening for small molecule inhibitors of the nsp14 RNA cap
methyltransferase. bioRxiv.
Bulut C, Kato Y (2020). Epidemiology of COVID-19. Turkish Journal
of Medical Sciences 50: 563-570.
Canal B, McClure AW, Curran JF, Wu M, Ulferts R et al. (2021).
Identifying SARS-CoV-2 antiviral compounds by screening
for small molecule inhibitors of Nsp14/nsp10 exoribonuclease.
bioRxiv 2021.2004.2007.438812
Chang L-J, Chen T-H (2021). NSP16 2′-O-MTase in coronavirus
pathogenesis: possible prevention and treatments strategies.
Viruses 13: 538.
Chen Y, Su C, Ke M, Jin X, Xu L et al. (2011). Biochemical and
structural insights into the mechanisms of SARS coronavirus
RNA ribose 2′-O-methylation by nsp16/nsp10 protein
complex. PLoS Pathog 7: e1002294.

Dai W, Zhang B, Jiang X-M, Su H, Li J et al. (2020). Structure-based
design of antiviral drug candidates targeting the SARS-CoV-2
main protease. Science 368: 1331-1335.
Decroly E, Debarnot C, Ferron F, Bouvet M, Coutard B et al.
(2011). Crystal structure and functional analysis of the SARScoronavirus RNA cap 2′-O-methyltransferase nsp10/nsp16
complex. PLoS Pathog 7: e1002059.
Den Boon JA, Ahlquist P (2010). Organelle-like membrane
compartmentalization of positive-strand RNA virus replication
factories. Annual Review of Microbiology 64: 241-256.
Farias AB, Candiotto G, Siragusa L, Goracci L, Cruciani G et al.
(2021). Targeting Nsp9 as an anti-SARS-CoV-2 strategy. New
Journal of Chemistry 45: 522-525.
Freitas BT, Durie IA, Murray J, Longo JE, Miller HC et al.
(2020). Characterization and noncovalent inhibition of the
deubiquitinase and deISGylase activity of SARS-CoV-2
papain-like protease. ACS Infectious Diseases 6: 2099-2109.
Gadhave K, Kumar P, Kumar A, Bhardwaj T, Garg N et al. (2020).
NSP 11 of SARS-CoV-2 is an intrinsically disordered protein.
bioRxiv
Gadhave K, Kumar P, Kumar A, Bhardwaj T, Garg N et al. (2021).
Conformational dynamics of 13 amino acids long NSP11 of
SARS-CoV-2 under membrane mimetics and different solvent
conditions. Microbial Pathogenesis 105041
Gao Y, Yan L, Huang Y, Liu F, Zhao Y et al. (2020). Structure of the
RNA-dependent RNA polymerase from COVID-19 virus.
Science 368: 779-782.

Chien M, Anderson TK, Jockusch S, Tao C, Li X et al. (2020).
Nucleotide analogues as inhibitors of SARS-CoV-2 Polymerase,
a key drug target for COVID-19. Journal of Proteome Research
19: 4690-4697.

Glaab E, Manoharan GB, Abankwa D (2021). A pharmacophore
model for SARS-CoV-2 3CLpro small molecule inhibitors and
in vitro experimental validation of computationally screened
inhibitors. bioRxiv.

Clark LK, Green TJ, Petit CM, Dutch RE (2021). Structure of
nonstructural protein 1 from SARS-CoV-2. Journal of Virology
95.

Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA et al.
(2004). Ultrastructural characterization of SARS coronavirus.
Emerging Infectious Diseases 10: 320-326.

Coelho C, Gallo G, Campos CB, Hardy L, Würtele M (2020).
Biochemical screening for SARS-CoV-2 main protease
inhibitors. PloS one 15: e0240079.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K et al. (2020).
A SARS-CoV-2 protein interaction map reveals targets for
drug repurposing. Nature 583: 459-468.

Cornillez-Ty CT, Liao L, Yates JR, Kuhn P, Buchmeier MJ (2009).
Severe acute respiratory syndrome coronavirus nonstructural
protein 2 interacts with a host protein complex involved in
mitochondrial biogenesis and intracellular signaling. Journal
of Virology 83: 10314-10318.

Greig SL (2016). Sofosbuvir/velpatasvir: a review in chronic hepatitis
C. Drugs 76: 1567-1578.

480

Griffin JWD (2020). SARS-CoV and SARS-CoV-2 main protease
residue interaction networks change when bound to inhibitor
N3. Journal of Structural Biology 211: 107575.

KOCABAŞ and USLU / Turk J Biol
Güler G, Özdemir H, Omar D, Akdoğan G (2021). Coronavirus
disease 2019 (COVID-19): Biophysical and biochemical
aspects of SARS-CoV-2 and general characteristics. Progress
in Biophysics and Molecular Biology.

Kim Y, Wower J, Maltseva N, Chang C, Jedrzejczak R et
al. (2021). Tipiracil binds to uridine site and inhibits
Nsp15 endoribonuclease NendoU from SARS-CoV-2.
Communications Biology 4.

Gupta M, Azumaya CM, Moritz M, Pourmal S, Diallo A et al. (2021).
CryoEM and AI reveal a structure of SARS-CoV-2 Nsp2, a
multifunctional protein involved in key host processes. bioRxiv.

Klemm T, Ebert G, Calleja DJ, Allison CC, Richardson LW et al.
(2020). Mechanism and inhibition of the papain‐like protease,
PLpro, of SARS‐CoV‐2. The EMBO Journal 39.

Hagemeijer M, Rottier P, Haan C (2012). Biogenesis and dynamics
of the coronavirus replicative structures. Viruses 4: 3245-3269.

Kocabas F, Aslan GS (2015). Fluorometric CCHFV OTU protease
assay with potent inhibitors. Virus Genes 51: 190-197.

Hasöksüz M, Kiliç S, Saraç F (2020). Coronaviruses and SARSCOV-2. Turkish Journal of Medical Sciences 50: 549-556.

Kocabaş F, Ergin EK (2016). Identification of small molecule binding
pocket for inhibition of Crimean–Congo hemorrhagic fever
virus OTU protease. Turkish Journal of Biology 40: 239-249.

Hoffmann HH, Sánchez-Rivera FJ, Schneider WM, Luna JM, SotoFeliciano YM et al. (2021). Functional interrogation of a SARSCoV-2 host protein interactome identifies unique and shared
coronavirus host factors. Cell Host & Microbe 29: 267-280.
e265.
Iketani S, Forouhar F, Liu H, Hong SJ, Lin F-Y et al. (2021). Lead
compounds for the development of SARS-CoV-2 3CL protease
inhibitors. Nature Communications 12.
Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B et al.
(2006). A second, non-canonical RNA-dependent RNA
polymerase in SARS Coronavirus. The EMBO Journal 25:
4933-4942.
Jena AB, Kanungo N, Nayak V, Chainy GBN, Dandapat J (2021).
Author correction: catechin and curcumin interact with S
protein of SARS-CoV2 and ACE2 of human cell membrane:
insights from computational studies. Scientific reports 11.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B et al. (2020).
Structure of Mpro from SARS-CoV-2 and discovery of its
inhibitors. Nature 582: 289-293.
Jin Z, Zhao Y, Sun Y, Zhang B, Wang H et al. (2020). Structural
basis for the inhibition of SARS-CoV-2 main protease by
antineoplastic drug carmofur. Nature Structural & Molecular
Biology 27: 529-532.
Kasprzyk R, Spiewla TJ, Golojuch S, Vangeel L, Jonghe SD et al.
(2021). Identification and evaluation of potential SARSCoV-2 antiviral agents targeting mRNA cap guanine N7methyltransferase. Antiviral Research 193: 105142.
Khalili Yazdi A, Li F, Devkota K, Perveen S, Ghiabi P et al. (2021).
A high-throughput radioactivity-based assay for screening
SARS-CoV-2 nsp10-nsp16 complex. SLAS DISCOVERY:
Advancing the Science of Drug Discovery 26: 757-765.
Kim N-E, Kim D-K, Song Y-J (2021). SARS-CoV-2 nonstructural
proteins 1 and 13 suppress caspase-1 and the NLRP3
inflammasome activation. Microorganisms 9: 494.
Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M et al.
(2020). Crystal structure of Nsp15 endoribonuclease NendoU
from SARS‐CoV‐2. Protein Science 29: 1596-1605.
Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M et al.
(2020). Crystal structure of Nsp15 endoribonuclease NendoU
from SARS‐CoV‐2. Protein Science 29: 1596-1605.

Kocabas F, Turan RD, Aslan GS (2015). Fluorometric RdRp assay
with self-priming RNA. Virus genes 50: 498-504.
Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F et al. (2021).
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
Nature Communications 12.
Kuo C-J, Chao T-L, Kao H-C, Tsai Y-M, Liu Y-K et al. (2021). Kinetic
characterization and Inhibitor Screening for the Proteases
Leading to Identification of Drugs against SARS-CoV-2.
Antimicrobial Agents and chemotherapy 65:
Levine B (2005). Eating oneself and uninvited guests. Cell 120: 159162.
Lin S, Chen H, Ye F, Chen Z, Yang F et al. (2020). Crystal structure of
SARS-CoV-2 nsp10/nsp16 2′-O-methylase and its implication
on antiviral drug design. Signal Transduction and Targeted
Therapy 5: 1-4.
Littler DR, Gully BS, Colson RN, Rossjohn J (2020). Crystal structure
of the SARS-CoV-2 non-structural protein 9, Nsp9. Iscience
23: 101258.
Liu C, Boland S, Scholle MD, Bardiot D, Marchand A et al. (2021).
Dual inhibition of SARS-CoV-2 and human rhinovirus with
protease inhibitors in clinical development. Antiviral Research
187: 105020.
Lu G, Zhang X, Zheng W, Sun J, Hua L, Xu L et al. (2020).
Development of a simple in vitro assay to identify and evaluate
nucleotide analogs against SARS-CoV-2 RNA-dependent RNA
polymerase. Antimicrobial Agents and Chemotherapy 65.
Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y et al. (2020).
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit
SARS-CoV-2 viral replication by targeting the viral main
protease. Cell Research 30: 678-692.
Maio N, Lafont BAP, Sil D, Li Y, Bollinger JM et al. (2021).
Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA
polymerase are potential antiviral targets. Science eabi5224
Mali SN (2020). The rise of new coronavirus infection-(COVID-19):
a recent update. Eurasian Journal of Medicine and Oncology .
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M et al. (2020).
The Inhaled steroid ciclesonide blocks SARS-CoV-2 RNA
replication by targeting the viral replication-transcription
complex in cultured cells. Journal of Virology 95 (1): e0164820. doi: 10.1128/JVI.01648-20.

481

KOCABAŞ and USLU / Turk J Biol
McClain CB, Vabret N (2020). SARS-CoV-2: the many pros of
targeting PLpro. Signal Transduction and Targeted Therapy 5.
Mengist HM, Dilnessa T, Jin T (2021). Structural basis of potential
inhibitors targeting SARS-CoV-2 main protease. Frontiers in
Chemistry 9.
Mengist HM, Fan X, Jin T (2020). Designing of improved drugs for
COVID-19: crystal structure of SARS-CoV-2 main protease
Mpro. Signal Transduction and Targeted Therapy 5.
Mutlu O, Ugurel OM, Sariyer E, Ata O, Inci TG et al. (2020).
Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with
approved and investigational drugs: an in silico structurebased approach. Journal of Biomolecular Structure and
Dynamics 1-13.
Naydenova K, Muir KW, Wu L-F, Zhang Z, Coscia F et al. (2021).
Structure of the SARS-CoV-2 RNA-dependent RNA
polymerase in the presence of favipiravir-RTP. Proceedings of
the National Academy of Sciences 118: e2021946118.
Osipiuk J, Azizi S-A, Dvorkin S, Endres M, Jedrzejczak R et al.
(2021). Structure of papain-like protease from SARS-CoV-2
and its complexes with non-covalent inhibitors. Nature
communications 12:1-9
Pandey P, Prasad K, Prakash A, Kumar V (2020). Insights into the
biased activity of dextromethorphan and haloperidol towards
SARS-CoV-2 NSP6: in silico binding mechanistic analysis.
Journal of Molecular Medicine 98: 1659-1673.
Paul AV, Wimmer E (2015). Initiation of protein-primed picornavirus
RNA synthesis. Virus Research 206: 12-26.
Peng Q, Peng R, Yuan B, Zhao J, Wang M et al. (2020). Structural
and biochemical characterization of the nsp12-nsp7-nsp8
core polymerase complex from SARS-CoV-2. Cell Reports 31:
107774.
Perveen S, Khalili Yazdi A, Devkota K, Li F, Ghiabi P et al. (2021). A
high-throughput RNA displacement assay for screening SARSCoV-2 nsp10-nsp16 complex toward developing therapeutics
for COVID-19. SLAS DISCOVERY: sdvancing the Science of
Drug Discovery 26: 620-627.
Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E (2020).
COVID-19, SARS and MERS: are they closely related? Clinical
Microbiology and Infection 26: 729-734.
Pitsillou E, Liang J, Ververis K, Lim KW, Hung A et al. (2020).
Identification of Small molecule inhibitors of the
deubiquitinating activity of the SARS-CoV-2 papain-like
protease: in silico molecular docking studies and in vitro
enzymatic activity assay. Frontiers in Chemistry 8.

Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S et al. (2020).
3C-like protease inhibitors block coronavirus replication in
vitro and improve survival in MERS-CoV–infected mice.
Science Translational Medicine 12: eabc5332.
Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC et al.
(2006). Severe acute respiratory syndrome coronavirus papainlike protease: structure of a viral deubiquitinating enzyme.
Proceedings of the National Academy of Sciences 103: 57175722.
Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N et al. (2020).
A Large-scale Drug Repositioning Survey for SARS-CoV-2
Antivirals. bioRxiv.
Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N et al. (2020).
Discovery of SARS-CoV-2 antiviral drugs through large-scale
compound repurposing. Nature 586: 113-119.
Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, DeJesus
E et al. (2013). Sofosbuvir (GS-7977) plus peginterferon/
ribavirin in treatment-naïve patients with HCV genotype 1: a
randomized, 28-day, dose-ranging trial. Journal of Hepatology
58: 663-668.
Sakai Y, Kawachi K, Terada Y, Omori H, Matsuura Y et al. (2017).
Two-amino acids change in the nsp4 of SARS coronavirus
abolishes viral replication. Virology 510: 165-174.
Schoggins JW, Rice CM (2011). Interferon-stimulated genes and
their antiviral effector functions. Current Opinion in Virology
1: 519-525.
Sharma M, Prasher P, Mehta M, Zacconi FC, Singh Y et al. (2020).
Probing 3CL protease: rationally designed chemical moieties
for COVID‐19. Drug Development Research 81: 911-918.
Sharun K, Tiwari R, Dhama K (2021). Protease inhibitor GC376 for
COVID-19: lessons learned from feline infectious peritonitis.
Annals of Medicine and Surgery 61: 122-125.
Sheahan TP, Sims AC, Zhou S, Graham RL, Hill CS et al. (2020).
An orally bioavailable broad-spectrum antiviral inhibits SARSCoV-2 and multiple endemic, epidemic and bat coronavirus.
bioRxiv 2020. 2003.2019.997890
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ et al. (2020).
An orally bioavailable broad-spectrum antiviral inhibits SARSCoV-2 in human airway epithelial cell cultures and multiple
coronaviruses in mice. Science Translational Medicine 12:
eabb5883.
Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K et al. (2020).
Papain-like protease regulates SARS-CoV-2 viral spread and
innate immunity. Nature 587: 657-662.

Pruijssers AJ, Denison MR (2019). Nucleoside analogues for the
treatment of coronavirus infections. Current Opinion in
Virology 35: 57-62.

Sies H, Parnham MJ (2020). Potential therapeutic use of ebselen for
COVID-19 and other respiratory viral infections. Free Radical
Biology and Medicine 156: 107-112.

Qiao J, Li Y-S, Zeng R, Liu F-L, Luo R-H et al. (2021). SARS-CoV-2
Mpro inhibitors with antiviral activity in a transgenic mouse
model. Science 371: 1374-1378.

Su H, Yao S, Zhao W, Li M, Liu J et al. (2020). Discovery of baicalin
and baicalein as novel, natural product inhibitors of SARSCoV-2 3CL protease in vitro. BioRxiv.

482

KOCABAŞ and USLU / Turk J Biol
Subissi L, Imbert I, Ferron F, Collet A, Coutard B et al. (2014a).
SARS-CoV ORF1b-encoded nonstructural proteins 12–16:
replicative enzymes as antiviral targets. Antiviral Research 101:
122-130.
Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC,
Gorbalenya AE et al. (2014b). One severe acute respiratory
syndrome coronavirus protein complex integrates processive
RNA polymerase and exonuclease activities. Proceedings of
the National Academy of Sciences 111: E3900-E3909.
Suryawanshi RK, Koganti R, Agelidis A, Patil CD, Shukla D (2021).
Dysregulation of cell signaling by SARS-CoV-2. Trends in
Microbiology 29: 224-237.
Taştan C, Yurtsever B, Sir Karakuş G, Dilek Kançağı D, Demir S et al.
(2020). SARS-CoV-2 isolation and propagation from Turkish
COVID-19 patients. Turkish Journal of Biology 44: 192-202.
Te Velthuis AJW, Van Den Worm SHE, Snijder EJ (2012). The SARScoronavirus nsp7+nsp8 complex is a unique multimeric RNA
polymerase capable of both de novo initiation and primer
extension. Nucleic Acids Research 40:1737-1747
Tidu A, Janvier A, Schaeffer L, Sosnowski P, Kuhn L et al. (2021). The
viral protein NSP1 acts as a ribosome gatekeeper for shutting
down host translation and fostering SARS-CoV-2 translation.
Rna 27: 253-264.
Ullrich S, Nitsche C (2020). The SARS-CoV-2 main protease as drug
target. Bioorganic & Medicinal Chemistry Letters 30: 127377.
van Dijk AA, Makeyev EV, Bamford DH (2004). Initiation of viral
RNA-dependent RNA polymerization. Journal of General
Virology 85: 1077-1093.
Vuong W, Fischer C, Khan MB, Van Belkum MJ, Lamer T et al.
(2021). Improved SARS-CoV-2 Mpro inhibitors based on feline
antiviral drug GC376: structural enhancements, increased
solubility, and micellar studies. European Journal of Medicinal
Chemistry 222:113584
Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T et al. (2020).
Feline coronavirus drug inhibits the main protease of SARSCoV-2 and blocks virus replication. Nature Communications
11.
Wang C-W, Klionsky DJ (2003). The molecular mechanism of
autophagy. Molecular Medicine 9: 65-76.
Wang M, Cao R, Zhang L, Yang X, Liu J et al. (2020). Remdesivir
and chloroquine effectively inhibit the recently emerged novel
coronavirus (2019-nCoV) in vitro. Cell Research 30: 269-271.

Wang Q, Wu J, Wang H, Gao Y, Liu Q et al. (2020). Structural basis
for RNA replication by the SARS-CoV-2 polymerase. Cell 182:
417-428. e413.
Wang Y, Lv Z, Chu Y (2015). HIV protease inhibitors: a review of
molecular selectivity and toxicity. HIV/AIDS - Research and
Palliative Care 95.
Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL et al.
(2014). Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature 508: 402-405.
White MA, Lin W, Cheng X (2020). Discovery of COVID-19
inhibitors targeting the SARS-CoV-2 Nsp13 helicase. The
Journal of Physical Chemistry Letters 11: 9144-9151.
Xie M, Chen Q (2020). Insight into 2019 novel coronavirus — an
updated interim review and lessons from SARS-CoV and
MERS-CoV. International Journal of Infectious Diseases 94:
119-124.
Yoshimoto FK (2020). The proteins of severe acute respiratory
syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the
cause of COVID-19. The Protein Journal 39: 198-216.
Ysrafil Y, Astuti I, Mus R, Gama NI, Rahmaisyah D et al. (2020). A
summary of coronavirus disease 2019: what we should know?
Pharmaceutical Sciences 26: S24-S35.
Yuen C-K, Lam J-Y, Wong W-M, Mak L-F, Wang X et al. (2020).
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent
interferon antagonists. Emerging Microbes & Infections 9:
1418-1428.
Zhang C-h, Wang Y-f, Liu X-j, Lu J-H, Qian C-w et al. (2005).
Antiviral activity of cepharanthine against severe acute
respiratory syndrome coronavirus in vitro. Chinese medical
journal 118: 493-496.
Zhang L, Lin D, Sun X, Curth U, Drosten C et al. (2020). Crystal
structure of SARS-CoV-2 main protease provides a basis for
design of improved α-ketoamide inhibitors. Science 368: 409412.
Zhu W, Shyr ZA, Lo DC, Zheng W (2021). Viral proteases as targets
for COVID-19 drug development. Journal of Pharmacology
and Experimental Therapeutics JPET-MR-2021-000688

483

